Scottsdale, Arizona, Jan. 9, 2013 (GLOBE NEWSWIRE) -- Provista Diagnostics, Inc., a leading molecular diagnostics
company, is pleased to announce the addition of new contract
research services and technologies to be offered to the
pharmaceutical and biotechnology industries by its Provista Dx
Reference Laboratory. These new services, combined with the
company's existing complement of development and testing services,
allow Provista to offer its customers a complete solution to their
laboratory needs, including consultation, assay evaluation and
development, method development, clinical laboratory services,
clinical trial design and diagnostic support, analytical regulatory
guidance and companion diagnostics. Furthermore, the Provista
Dx Reference Laboratory offers a comprehensive array of
technologies, such as qualitative and quantitative
immunohistochemistry, advanced protein analysis (ELISA, Luminex and
MSD) and next generation sequencing (Real Time qPCR, Ion
Torrent).

The Provista Dx Reference Laboratory, which is both
CLIA-accredited and GLP capable, is licensed in 48 states to
perform human clinical testing and offers a comprehensive menu of
testing services, including custom projects, companion diagnostics
and clinical trial support. The laboratory is managed by
experienced research, method development, clinical and commercial
laboratory scientists and has a strong Quality Management Program
with significant training requirements for all staff members.
The laboratory scientists have expertise in assessing, evaluating
and bringing new analytical technologies to the commercial
marketplace. In addition, Provista is committed to adhering
to this same level of quality as it expands the capabilities of its
New York City facility.

Building upon the experience of management, the laboratory and
its staff has enabled Provista Diagnostics to adopt a two-pronged
commercialization strategy. This strategy allows Provista to
align its resources to provide validation and development services
needed for companion diagnostics, clinical trial support and other
custom projects, and also to continue to pursue the development and
commercialization of its own proprietary diagnostic, prognostic and
predictive tests for women's cancers, including breast, endometrial
and ovarian. With the company's current offerings, a series
of recent hires to complement the experienced staff, and a strong
Scientific Advisory Board comprised of recognized leaders in the
fields of oncology and biomarker research, Provista Diagnostics is
rapidly becoming a highly regarded, world class laboratory
facility.

About CLIA

Clinical Laboratory Improvement Amendments (CLIA) of 1988 are
United States federal regulatory standards that apply to all
clinical laboratory testing performed on humans in the United
States, except clinical trials and basic research. The
objective of CLIA is to ensure the accuracy, reliability and
timeliness of test results regardless of where the test was
performed. A CLIA lab is a laboratory that operates under
CLIA supervision and is defined as a facility that performs
testing on materials derived from the human body for the
purpose of providing information for the diagnosis,
prevention, or treatment of any disease or impairment of, or
assessment of the health of, human beings. In total, CLIA
covers approximately 225,000 laboratory entities, most located in
the United States.

About Provista Diagnostics, Inc.

Provista Diagnostics, Inc., a Delaware corporation, offers
comprehensive testing services through its CLIA-accredited Provista
Dx Reference Laboratory to support the development of companion
diagnostics and clinical trials, while developing and
commercializing breakthrough, easy to administer blood-based
diagnostic tests for early oncology-related disease state
recognition and detection purposes. Near term development and
commercialization efforts focus on women's cancers such as breast,
endometrial and ovarian cancer.

Easily Send & Share Press Releases

GlobeNewswire, a NASDAQ OMX company, is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.